Anderson Karen M.'s Form 4/A amendment
AmendedCentessa Pharmaceuticals plc (CNTA) · filed Mar 16, 2026
- Accession no.
- 0001470831-26-000279
- Filed
- Mar 16, 2026
- Trade date
- Mar 13, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
- Original filed
- Mar 13, 2026
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.15M. It was filed 3 days after the trade.
This amendment replaces 0001470831-26-000268 (filed Mar 13, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Anderson Karen M.CIK 0001762176 | Officer (Chief People Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Ordinary Shares | MOption exerciseAcquired | +94,224 | $4.01 | +$377,838.24 | 166,940 | Direct | |
| Mar 13, 2026 | Ordinary Shares | MOption exerciseAcquired | +15,174 | $3.85 | +$58,419.9 | 182,114 | Direct | |
| Mar 13, 2026 | Ordinary Shares | SSaleDisposed | −107,961 | $26.15F3 | −$2,823,180.15 | 74,153 | Direct | |
| Mar 13, 2026 | Ordinary Shares | SSaleDisposed | −12,068 | $27.13F4 | −$327,404.84 | 62,085 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2026 | Ordinary Shares | MOption exerciseDisposed | −94,224 | $0.00 | $0 | 149,811 | Direct | |
| Mar 13, 2026 | Ordinary Shares | MOption exerciseDisposed | −15,174 | $0.00 | $0 | 28,336 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.75 to $26.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.805 to $27.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F5
25% of the shares subject to such option shall vest and become exercisable on December 1, 2023 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.
- F6
1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Remarks
This Form 4/A amends and restates the Form 4 filed on March 13, 2026 to correct the reporting of stock option exercises. The exercises were previously reported as originating from a single option grant but were exercised from two separate option grants with different exercise prices. This amendment reports the exercises from each grant at the applicable exercise prices. Except for the corrected reporting of the option exercises, the transactions and amounts previously reported remain unchanged.